Brincidofovir

Brincidofovir
Clinical data
Trade names	Tembexa
Other names	CMX001; Cidofovir-HDP; hexadecyloxypropyl-cidofovir
License data	US DailyMed: Brincidofovir;
Routes of; administration	By mouth
ATC code	J05AB17 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid;
CAS Number	444805-28-1 ; Sodium salt: 496765-79-8 ;
PubChem CID	483477;
DrugBank	DB12151; Sodium salt: DBSALT002145;
ChemSpider	424003; Sodium salt: 21259112;
UNII	6794O900AX; Sodium salt: 8UN8SA9Z5C ;
KEGG	D10547;
ChEMBL	ChEMBL203321;
CompTox Dashboard (EPA)	DTXSID60196190 ;
Chemical and physical data
Formula	C27H52N3O7P
Molar mass	561.701 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)Cn1ccc(N)nc1=O;
	InChI InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1; Key:WXJFKKQWPMNTIM-VWLOTQADSA-N;

Brincidofovir, sold under the brand name Tembexa, is an antiviral drug used to treat smallpox. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability.

The most common side effects include diarrhea, nausea, vomiting, and abdominal pain. It carries an FDA-mandated black box warning of an increased risk of death with extended use. Brincidofovir was approved for medical use in the United States in June 2021.